The overall trend observed across all forecasts indicates a significant decline in COVID-19 mortality rates over the period from 2020-2025. The projections vary considerably, reflecting uncertainties surrounding viral evolution, public health interventions, and vaccine effectiveness. However, a consistent theme emerges: the pandemic’s impact will diminish substantially as immunity increases and the virus transitions towards a more manageable, seasonal illness, similar to influenza.

The rationale for this projection centers on the observed decline in COVID-19 mortality rates driven by several factors: widespread vaccination, the development of natural immunity through prior infections, and improved medical treatments. The trend suggests a gradual shift from a devastating global pandemic to a more controlled, seasonal illness.  The rate of this decline is not uniform, with some forecasts projecting a more rapid decrease while others anticipate a slower, more gradual transition. 

A key element underpinning these forecasts is the recognition that the SARS-CoV-2 virus will continue to evolve. While immunity from vaccination and prior infection will play a crucial role in mitigating the pandemic’s impact, there remains a possibility of new variants emerging that could possess increased transmissibility or virulence. The emergence of such variants could temporarily halt the downward trend in mortality rates, requiring renewed public health measures and potentially new vaccine formulations.

Furthermore, the forecasts acknowledge the expectations of experts and markets, which generally reflect a cautious optimism based on the observed decline in COVID-19 mortality rates. Investment in healthcare and pharmaceutical companies is likely to continue, albeit with a degree of sensitivity to any announcement of a particularly virulent variant.

Despite this overall optimistic outlook, the projections recognize the potential for significant variation. A ‘worst-case’ scenario involves the emergence of a highly transmissible and virulent variant that overwhelms existing immunity and public health systems, leading to a substantial increase in mortality rates. Conversely, a ‘best-case’ scenario assumes the rapid development and deployment of a highly effective vaccine that provides near-universal protection against all known and future variants of SARS-CoV-2, effectively eliminating the virus as a significant public health threat. 

Considering all the forecasts, a reasonable projected annual death toll for the period 2020-2025, factoring in potential fluctuations based on viral evolution, ranges from approximately 50,000 to 800,000 globally. This range reflects the inherent uncertainties and acknowledges that the ultimate outcome will depend on a complex interplay of factors beyond the immediate control of public health officials.

### Forecast

Percentile 10: 10000.0
Percentile 20: 25000.0
Percentile 40: 50000.0
Percentile 60: 75000.0
Percentile 80: 100000.0
Percentile 90: 120000.0